Voyager Therapeutics, Inc. (VYGR) Balance Sheet
As of 2026-06-30 (10-Q), Voyager Therapeutics, Inc. (VYGR) reported total assets of $197.8M, total liabilities of $43.4M and shareholders' equity of $154.4M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $35.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VYGRVoyager Therapeutics, Inc.Follow VYGR — free
—
Price chart with a free account
- Market cap
- 107.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 31.3 | 36.6 | 31.5 | 46.9 | 86.0 | 104.4 | 117.4 | 99.0 | 68.8 | 71.4 | 65.3 | 35.8 | |
| Short-term investments | 163.0 | 137.8 | 137.5 | 108.9 | 195.5 | 76.7 | 15.1 | 19.9 | 162.1 | 195.3 | 131.1 | 80.6 | |
| Receivables | — | — | — | — | — | — | — | — | 80.2 | 1.5 | 1.8 | 2.9 | |
| Current assets | 195.9 | 178.8 | 171.8 | 162.5 | 304.7 | 197.8 | 136.7 | 124.5 | 319.7 | 276.8 | 202.7 | 125.2 | |
| Total assets | 229.5 | 189.6 | 184.5 | 177.0 | 354.8 | 261.6 | 193.9 | 159.4 | 351.3 | 393.1 | 252.3 | 197.8 | |
| Current liabilities | 23.9 | 13.8 | 15.9 | 31.7 | 76.0 | 26.8 | 51.0 | 72.6 | 64.5 | 49.8 | 26.5 | 16.7 | |
| Total liabilities | 60.4 | 53.6 | 50.4 | 130.6 | 255.2 | 107.3 | 98.8 | 100.3 | 115.0 | 93.3 | 56.2 | 43.4 | |
| Shareholders' equity | 169.1 | 135.9 | 134.1 | 46.4 | 99.5 | 154.3 | 95.1 | 59.0 | 236.3 | 299.8 | 196.1 | 154.4 |
USD millions · SEC XBRL
Voyager Therapeutics, Inc. — questions
- How much cash does Voyager Therapeutics, Inc. have?
- $35.8M in cash and cash equivalents as of 2026-06-30.
- What are Voyager Therapeutics, Inc.'s total assets?
- $197.8M as of 2026-06-30.
- What is Voyager Therapeutics, Inc.'s shareholders' equity?
- $154.4M as of 2026-06-30.
Every figure on this page comes from Voyager Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.